Frisch Financial Group’s Biogen BIIB Stock Holding History

Frisch Financial Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,376	Closed	-$435K	–	98
2020 Q1	$435K	Hold	1,376	–	–	0.25%	56
2019 Q4	$408K	Buy	+1,376	New	+$382K	0.19%	64

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Frisch Financial Group's BIIB Position: Q2 2020 in Review

Frisch Financial Group sold out of Biogen (BIIB) in Q2 2020, closing a stake of 1,376 shares — an estimated $435K sold.

Frisch Financial Group first reported a position in BIIB in Q4 2019 and held it in 2 quarters. The position peaked at $435K in Q1 2020. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

Frisch Financial Group reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
Frisch Financial Group sold 1,376 Biogen shares in Q2 2020, an estimated $435K.
Frisch Financial Group first reported a position in Biogen in Q4 2019 and held it in 2 quarters.
Frisch Financial Group's Biogen position peaked at $435K in Q1 2020.
1,060 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Frisch Financial Group's 13F filing for Q2 2020, filed 6 Aug 2020.